Mirxes, XtalPi, and Sihelix Forge Alliance to Build AI-Driven Precision Prevention and Treatment Ecosystem for Gastric Cancer

Beijing News (Reporter Wang Kala) Recently, Mirxes, XtalPi, and SIGNET announced that the three parties will jointly build a precise prevention and treatment system for gastric cancer with AI at its core, covering the entire process of "early screening-diagnosis-treatment". They will also establish joint ventures in China and Singapore to leverage their respective strengths and jointly expand the Asian market.

The program relies on Mirxes' globally leading early gastric cancer screening technology and XtalPi's AI+RobotDrug Discovery Platform and SIGNET's World-First Diffuse Gastric Cancer Targeted Drug Pipeline to Gradually Build a Full-Cycle Treatment Closed-Loop System for Gastric Cancer in the Next Five Years, Comprehensively Enhancing Early Screening Penetration and Precision Diagnosis and Treatment Coverage for Gastric Cancer. This Effort Aims to Reduce the Incidence and Mortality of Gastric Cancer in Asia, Improve the Accessibility of Early Screening and Effectiveness of Treatment in China and Across Asia, and Strive to Systematically Decrease the Burden of Gastric Cancer on Patients' Families and Healthcare Systems by 2031. The Goal Is to Progressively Eliminate This Major Health Threat Through Technological Collaboration to Overcome Challenges in Gastric Cancer Prevention and Treatment.

Gastric cancer is a highly prevalent malignant tumor in Asia, with nearly half of the global gastric cancer deaths occurring in this region. In China, the annual number of new cases exceeds 350,000, with over 260,000 deaths. The majority of patients are diagnosed at an advanced stage, and difficult-to-treat subtypes such as diffuse gastric cancer lack effective treatment options. Insufficient early screening and delayed treatment have become the core challenges.

As a key part of the plan, XtalPi participated in the new share placement of MiRXES as a strategic investor and reached an in-depth technical cooperation. By the end of 2025, MiRXES and XtalPi have reached a strategic cooperation to jointly build an AI-enabled "integration of diagnosis and treatment" innovative research and industrialization platform, working together to create a full-chain solution from early detection to precise intervention and treatment.

Proofread by Wang Xin